Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 593 is a protein characterized by a classic C2H2-type zinc finger domain embedded within a predominantly intrinsically disordered framework[1][2][3][5]. It enables preribosome binding and zinc ion binding activity, and is involved in the positive regulation of transcription by RNA polymerase II[1][5]. ZNF593 acts as a negative modulator of the DNA-binding activity of the Oct-2 (a POU domain-containing transcription factor), thus influencing transcriptional regulatory activity[1][2][3][5]. The protein localizes primarily to the nucleolus and nucleoplasm[1][5]. Current literature does not identify ZNF593 as a direct therapeutic target, biomarker, or drug-interaction partner, nor is it directly linked to a major disease context; its principal recognized function is as a regulatory transcription factor associated with ribosome biogenesis and gene expression modulation[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 593 (ZNF593).